[1]寇芙蓉,刘巍. 复发转移性头颈鳞状细胞癌免疫治疗现状和探索[J]. 中华肿瘤防治杂志,2017,24:1102-1108. [2]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69:7-34. [3]Lee HM, Okuda KS, González FE, et al. Current perspectives on nasopharyngeal carcinoma[J]. Adv Exp Med Biol, 2019, 1164:11-34. [4]Zhang B, Li MM, Chen WH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. JAMA Netw Open, 2019, 2:e1913619. doi: 10.1001/jamanetworkopen.2019.13619. [5]沈兰超,张梅芹,许敏,等. 华蟾素肝动脉推注联合化疗药物热灌注治疗原发性肝癌的临床价值[J]. 东南国防医药,2020,22:292-294. [6]李要轩,梁惠. 华蟾素胶囊联合化疗治疗晚期胃癌的临床研究[J]. 现代消化及介入诊疗,2020,25:380-382. [7]金金,马银杰,何生奇. 华蟾素胶囊联合化疗治疗晚期结直肠癌的系统评价与Meta分析[J]. 中国中医基础医学杂志,2020,26:1312-1316. [8]Xie M, Chen X, Qin S, et al. Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia[J]. J Cancer Res Ther, 2018, 14:226-232. [9]Wang T, Zhang L, Han L, et al. Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors[J]. Pak J Pharm Sci, 2018, 31:1609-1612. [10]Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science[J]. Cancer Med, 2019, 8: 1958-1975. [11]de Sá Junior PL, Câmara DAD, Porcacchia AS, et al. The roles of ROS in cancer heterogeneity and therapy[J]. Oxid Med Cell Longev, 2017, 2017:2467940. doi: 10.1155/2017/2467940. [12]Yang Y, Karakhanova S, Hartwig W, et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy[J]. J Cell Physiol, 2016, 231:2570-2581. [13]刘铮,张元霞,周萍,等. 线粒体膜通透性增加引起凋亡机制的研究进展[J]. 哈尔滨医科大学学报,2015,50:90-93. [14]周洁,章卓,宋丽,等. 白藜芦醇对Aβ1-42刺激HUVECs后凋亡因子Bcl-2/Bax及线粒体跨膜电位的影响[J]. 基础医学与临床,2016,36:1108-1112. |